Look at Whole Prescribing Facts OPDIVO® (nivolumab) is indicated for your treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed just after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or just after 3 or more lines of systemic therapy that features autologous HSCT.b